TY - JOUR
T1 - PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease
AU - Schmidt, Amand F.
AU - Pearce, Lucy S.
AU - Wilkins, John T.
AU - Overington, John P.
AU - Hingorani, Aroon
AU - Casas, Juan Pablo
PY - 2015
Y1 - 2015
N2 - This is the protocol for a review and there is no abstract. The objectives are as follows: Primary To quantify the short (24 weeks), medium (one year), and long-term (five year) effects of PCSK9MABs on lipid parameters and CVD risk. Secondary To quantify the safety of PCSK9 MABs, specifically focusing on the incidence of type 2 diabetes, cognitive function, and cancer. Additionally, we will determine if treatment should be tailored to certain patient subgroups that are more or less likely to benefit from PCSK9 MABs.
AB - This is the protocol for a review and there is no abstract. The objectives are as follows: Primary To quantify the short (24 weeks), medium (one year), and long-term (five year) effects of PCSK9MABs on lipid parameters and CVD risk. Secondary To quantify the safety of PCSK9 MABs, specifically focusing on the incidence of type 2 diabetes, cognitive function, and cancer. Additionally, we will determine if treatment should be tailored to certain patient subgroups that are more or less likely to benefit from PCSK9 MABs.
UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85009876004&origin=inward
U2 - https://doi.org/10.1002/14651858.CD011748
DO - https://doi.org/10.1002/14651858.CD011748
M3 - Article
SN - 1469-493X
VL - 2015
JO - Cochrane Database of Systematic Reviews
JF - Cochrane Database of Systematic Reviews
IS - 6
M1 - CD011748
ER -